Paclitaxel Uses, Dosage, Side Effects and Interactions
Abraxane
Abraxane was approved by the FDA in January 2005 as an injection. An FDA-approved generic with the same active ingredient is listed.
Paclitaxel Protein Bound Particles Albumin Bound
Paclitaxel Protein Bound Particles Albumin Bound is a brand of paclitaxel that comes as an injection. An FDA-approved generic with the same active ingredient is listed.
Paclitaxel is a chemotherapy medicine used intravenously to treat certain breast, lung, ovarian, and pancreatic cancers, as well as AIDS-related Kaposi's sarcoma.
Quick links
Ask Anything About PaclitaxelType a question in your own words. Answered from its FDA label in seconds.Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.
Paclitaxel in Short
- Drug class Microtubule Inhibitor How the FDA classifies it
What it treatsPaclitaxel injection is used to treat advanced ovarian cancer (including as first-line therapy in combination with cisplatin), breast cancer after prior chemotherapy has failed, and non-small cell lung cancer in patients who are not candidates for surgery or radiation (in combination with cisplatin).
- How you get it Prescription only
- Comes asInjection (into a vein)
- The FDA’s strongest warningBoxed warning The FDA’s most serious alert. Read what it says
- Generic versionYes, FDA-approved Listed with the FDA, which does not mean every pharmacy stocks it
The Pharmacist’s Take
Paclitaxel is a chemotherapy given into a vein for breast, ovarian, non-small cell lung and pancreatic cancers and AIDS-related Kaposi's sarcoma, and it jams the internal scaffolding (microtubules) cancer cells need to divide; it has been a cornerstone of cancer treatment since about 1992, with FDA-approved generic versions listed. It is a demanding treatment, and the effects most people notice are hair loss, tiredness, aching joints and muscles, and numbness or tingling in the hands and feet. Its boxed warning is a severe drop in infection-fighting white blood cells (neutropenia), so blood counts are checked often, and any fever or chills means calling your care team right away.
Key Takeaways From the HelloPharmacist Team
- Expect each dose as an infusion into a vein at a clinic, lasting a few hours and most often given every 3 weeks.
- Tell your team early about numbness, tingling or weakness in your hands or feet, because worsening nerve damage may mean adjusting the dose.
- Standard paclitaxel, unlike albumin-bound Abraxane, comes with a steroid, antihistamine and acid reducer first; report breathing trouble or hives during infusion immediately.
- List every medicine for your team, since clarithromycin, ketoconazole, itraconazole, rifampin, carbamazepine and gemfibrozil can raise or lower paclitaxel levels.
FDA Boxed WarningThe FDA’s strongest safety alert. Read what it says about Paclitaxel.
Paclitaxel must be given under the supervision of a doctor experienced in cancer chemotherapy, and only where emergency treatment is immediately available. Severe allergic reactions — including life-threatening drops in blood pressure, difficulty breathing, swelling, and hives — have occurred in 2–4% of patients, and some have been fatal even in patients who received pre-medications. If you have a severe reaction, you must not receive paclitaxel again. Paclitaxel also causes significant drops in white blood cells (neutropenia), which can lead to serious infections. It should not be given if your neutrophil (infection-fighting white blood cell) count is too low at the start of treatment. Regular blood tests are required throughout treatment to monitor for this.
Patient Information Guide for Paclitaxel
What It’s Used For
Paclitaxel is a chemotherapy medicine given intravenously to treat several types of cancer. Specific approvals depend on the product formulation:
- Abraxane and albumin-bound paclitaxel products: Metastatic breast cancer after combination chemotherapy has failed; locally advanced or metastatic non-small cell lung cancer (first-line, with carboplatin); metastatic adenocarcinoma of the pancreas (first-line, with gemcitabine)
- Paclitaxel injection (solution/concentrate): Advanced ovarian cancer (as subsequent therapy, or first-line with cisplatin); breast cancer after chemotherapy failure; adjuvant treatment of node-positive breast cancer (given sequentially with standard chemotherapy); first-line non-small cell lung cancer in combination with cisplatin; second-line AIDS-related Kaposi's sarcoma
How It Works
Paclitaxel is a microtubule inhibitor. Microtubules are tiny structural rods inside cells that cells use to pull their chromosomes apart when dividing. Paclitaxel locks these rods in place, preventing the normal reorganization that must happen for a cell to divide. With the division machinery jammed, cancer cells cannot multiply and instead die off. It disrupts this process both during cell division (mitosis) and during the day-to-day life of the cell.
Drug Class
Drug Class
- Microtubule Inhibitor
Detailed classifications and sources
The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.
Drug Class
Established Pharmacologic Class (EPC)- Microtubule Inhibitor
The main drug class the FDA gives it. It is the class named on the drug’s label.
How It Works
Mechanism of action (MoA)None listed for Paclitaxel in the FDA’s index.
What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.
What It Does in the Body
Physiologic effect (PE)- Microtubule Inhibition
A change it makes in how the body works.
Chemical Family
Chemical structure (CS)None listed for Paclitaxel in the FDA’s index.
The chemical family it belongs to, by its structure.
Drug Family
WHO ATC classification- Taxanes
How the World Health Organization groups it: by the part of the body it acts on and what it treats.
The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.
Dosage
Paclitaxel is always given as an intravenous (IV) infusion in a clinic or hospital — never taken by mouth. The schedule varies by product and the condition being treated: it may be administered once every three weeks or on specific days within a multi-week cycle.
Your oncologist will determine your schedule based on which product you are receiving and what you are being treated for.
- Before each infusion of standard paclitaxel injection, pre-medications are required to reduce the risk of serious allergic reactions
- Albumin-bound formulations such as Abraxane must not be substituted for other paclitaxel products — they are different and not interchangeable
- Always follow your prescriber's and infusion team's instructions exactly; do not adjust your schedule without talking to your doctor
Typical Doses
Your prescriber chooses your dose, so take it exactly as prescribed.
Paclitaxel 6 mg/mL Injection
Ovarian cancer
Adults not treated before · 175 mg/m2 Usual dose 175 mg/m2 every 3 weeks
- Paclitaxel injection 175 mg/m2 intravenously over 3 hours followed by cisplatin 75 mg/m2, every 3 weeks
Adults not treated before · 135 mg/m2 Usual dose 135 mg/m2 every 3 weeks
- Paclitaxel injection 135 mg/m2 intravenously over 24 hours followed by cisplatin 75 mg/m2, every 3 weeks
Adults treated with chemotherapy before Dose 135 mg/m2 or 175 mg/m2
- 135 mg/m2 or 175 mg/m2 intravenously over 3 hours every 3 weeks
Breast cancer
Adults with node-positive breast cancer, after surgery Usual dose 175 mg/m2 every 3 weeks
- 175 mg/m2 intravenously over 3 hours every 3 weeks for 4 courses, sequentially after doxorubicin-containing combination chemotherapy
Adults whose cancer spread or returned after earlier chemotherapy Usual dose 175 mg/m2 every 3 weeks
- 175 mg/m2 intravenously over 3 hours every 3 weeks
Non-small cell lung cancer
For adults
Usual dose 135 mg/m2 every 3 weeks
- 135 mg/m2 intravenously over 24 hours followed by cisplatin 75 mg/m2, every 3 weeks
24 hour infusion: transaminase < 2 × ULN and bilirubin ≤ 1.5 mg/dL
For adults
Starting dose 135 mg/m2
Good to know
First course; reduce further based on tolerance
ULN means upper limit of normal, the top of the normal range for the test.
24 hour infusion: transaminase 2 to < 10 × ULN and bilirubin ≤ 1.5 mg/dL
For adults
Starting dose 100 mg/m2
Good to know
First course; reduce further based on tolerance
ULN means upper limit of normal, the top of the normal range for the test.
24 hour infusion: transaminase < 10 × ULN and bilirubin 1.6 to 7.5 mg/dL
For adults
Starting dose 50 mg/m2
Good to know
First course; reduce further based on tolerance
ULN means upper limit of normal, the top of the normal range for the test.
24 hour infusion: transaminase ≥ 10 × ULN or bilirubin > 7.5 mg/dL
For adults
Not recommended
ULN means upper limit of normal, the top of the normal range for the test.
3 hour infusion: transaminase < 10 × ULN and bilirubin ≤ 1.25 × ULN
For adults
Starting dose 175 mg/m2
Good to know
First course; reduce further based on tolerance
ULN means upper limit of normal, the top of the normal range for the test.
3 hour infusion: transaminase < 10 × ULN and bilirubin 1.26 to 2 × ULN
For adults
Starting dose 135 mg/m2
Good to know
First course; reduce further based on tolerance
ULN means upper limit of normal, the top of the normal range for the test.
Paclitaxel 100 Mg/20 mL and 100 Mg/100 Mg Injection
Breast cancer that has spread
Adults Usual dose 260 mg/m2 every 3 weeks
- 260 mg/m2 intravenously over 30 minutes every 3 weeks
Adults with moderate liver problems Starting dose 200 mg/m2
Good to know
First course; consider increase to 260 mg/m2 if tolerated for two cycles
Adults with severe liver problems Starting dose 200 mg/m2
Good to know
First course; consider increase to 260 mg/m2 if tolerated for two cycles
Non-small cell lung cancer
Adults Usual dose 100 mg/m2 on Days 1, 8, and 15 of each 21-day cycle
- 100 mg/m2 intravenously over 30 minutes on Days 1, 8, and 15 of each 21-day cycle
- Carboplatin on Day 1 of each cycle immediately after
Adults with moderate liver problems Starting dose 80 mg/m2
Good to know
First course; consider increase to 100 mg/m2 if tolerated for two cycles
Pancreatic cancer that has spread
For adults
Usual dose 125 mg/m2 on Days 1, 8, and 15 of each 28-day cycle
- 125 mg/m2 intravenously over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle
- Gemcitabine immediately after
Side Effects
Paclitaxel commonly causes a range of side effects because it affects both cancer cells and some healthy cells:
Common side effects
- Low white blood cell counts (neutropenia), raising infection risk
- Numbness, tingling, or pain in hands and feet (peripheral neuropathy)
- Hair loss
- Nausea and vomiting
- Joint and muscle aches
- Fatigue
- Diarrhea
- Mouth sores (mucositis)
When to get medical help
- Signs of a severe allergic reaction: trouble breathing, sudden drop in blood pressure, swelling of the face or throat, or widespread hives — seek emergency help immediately
- Signs of serious infection or sepsis: fever (even without low white blood cell counts), chills, or feeling very unwell — call your care team right away
- Severe numbness, tingling, or weakness in hands or feet that gets worse — tell your doctor; dose adjustment may be needed
- Breathing problems such as new or worsening shortness of breath or cough — may signal pneumonitis (lung inflammation)
- Signs of bone marrow suppression: unusual bruising, bleeding, or signs of infection
Contact your care team right away if you develop a fever, have trouble breathing, notice severe or worsening numbness or weakness in your limbs, or experience signs of an allergic reaction — these can be serious and need prompt attention.
Warnings and Precautions
- Severe bone marrow suppression (neutropenia): The most common serious risk — low white blood cell counts can lead to life-threatening infections. Blood counts must be checked regularly, and treatment may need to be paused or the dose reduced.
- Severe allergic reactions (hypersensitivity/anaphylaxis): Can be life-threatening. Fatal reactions have occurred even with pre-medications. Anyone who has had a severe reaction must not receive paclitaxel again.
- Severe nerve damage (sensory neuropathy): Worsening numbness or tingling may require dose reduction or treatment breaks.
- Sepsis (bloodstream infection): Especially when albumin-bound paclitaxel is combined with gemcitabine; fever should be reported immediately.
- Pneumonitis (lung inflammation): Has occurred with albumin-bound paclitaxel plus gemcitabine, including fatal cases; any new breathing problems should be reported right away.
- Fetal harm: Paclitaxel can seriously harm an unborn baby. Effective contraception is required during treatment and for months after the last dose.
- Liver impairment: Can increase paclitaxel exposure and toxicity; dose reduction may be needed and certain uses are not recommended in severe liver impairment.
Interactions
Paclitaxel is broken down by liver enzymes (CYP2C8 and CYP3A4), so medicines that affect those enzymes can change how much paclitaxel is in your body:
- Cisplatin: Giving cisplatin before paclitaxel (rather than after) can reduce paclitaxel clearance by about one-third, increasing its effects and side effects — the order of administration matters
- CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, saquinavir, nefazodone): May increase paclitaxel levels, raising the risk of toxicity
- CYP3A4 inducers (e.g., rifampin, carbamazepine): May lower paclitaxel levels, potentially reducing effectiveness
- CYP2C8 inhibitors (e.g., gemfibrozil): May increase paclitaxel exposure
- CYP2C8 inducers (e.g., rifampin): May decrease paclitaxel exposure
- Doxorubicin: Blood levels of doxorubicin and its active breakdown product may be higher when used alongside paclitaxel
Interactions Listed in the FDA-Approved Label
From the Paclitaxel prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
-
CisplatinWhat happensMyelosuppression was more profound when paclitaxel was given after cisplatin, and paclitaxel clearance decreased by approximately 33%.What to doGive paclitaxel before cisplatin.
-
CYP3A4 substrates, inhibitors and inducers For example: midazolam, ketoconazole, ritonavir, rifampin, carbamazepineWhat happensPaclitaxel is metabolized by CYP3A4, so these drugs may interact with it.What to doExercise caution when given together.
-
CYP2C8 substrates, inhibitors and inducers For example: repaglinide, rosiglitazone, gemfibrozil, rifampinWhat happensPaclitaxel is metabolized by CYP2C8, so these drugs may interact with it.What to doExercise caution when given together.
-
Protease inhibitors (ritonavir, saquinavir, indinavir, nelfinavir)What happensPotential interactions with paclitaxel have not been evaluated in clinical trials.
-
What happensPlasma levels of doxorubicin and its active metabolite doxorubicinol may be increased when used with paclitaxel.What to doMonitor cardiac function when used for metastatic breast cancer.
-
Polyoxyl 35 Castor Oil products For example: cyclosporin for injection concentrate, teniposide for injection concentrateWhat happensPatients with a history of severe hypersensitivity reactions to these products should not be treated with paclitaxel.What to doDo not treat with paclitaxel.
Read the label’s full interactions text
Drug Interactions: In a Phase I trial using escalating doses of paclitaxel (110 to 200 mg/m 2 ) and cisplatin (50 or 75 mg/m 2 ) given as sequential infusions, myelosuppression was more profound when paclitaxel was given after cisplatin than with the alternate sequence (i.e., paclitaxel before cisplatin). Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when paclitaxel was administered following cisplatin. The metabolism of paclitaxel is catalyzed by cytochrome P450 isoenzymes CYP2C8 and CYP3A4. In the absence of formal clinical drug interaction studies, caution should be exercised when administering paclitaxel concomitantly with known substrates or inhibitors of the cytochrome P450 isoenzymes CYP2C8 and CYP3A4. Caution should be exercised when paclitaxel is concomitantly administered with known substrates (e.g., midazolam, buspirone, felodipine, lovastatin, eletriptan, sildenafil, simvastatin, and triazolam), inhibitors (e.g., atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin), and inducers (e.g., rifampin and carbamazepine) of CYP3A4. (See CLINICAL PHARMACOLOGY section.) Caution should also be exercised when paclitaxel is concomitantly administered with known substrates (e.g., repaglinide and rosiglitazone), inhibitors (e.g., gemfibrozil), and inducers (e.g., rifampin) of CYP2C8. (See CLINICAL PHARMACOLOGY. ) Potential interactions between paclitaxel, a substrate of CYP3A4, and protease inhibitors (ritonavir, saquinavir, indinavir, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials. Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination.
Excerpted: the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before You Start
- Your neutrophil (white blood cell) count must be above a safe minimum before each treatment — paclitaxel cannot be given if counts are too low
- Tell your doctor about any prior severe allergic reaction to paclitaxel or other taxane medicines (such as docetaxel) — this may be a contraindication
- Tell your doctor if you have liver disease or abnormal liver tests — dose reduction or avoiding certain formulations may be necessary
- Tell your doctor if you are pregnant, planning to become pregnant, or breastfeeding — paclitaxel can cause serious harm to a developing baby and should not be used in pregnancy; breastfeeding should be stopped during treatment and for two weeks after the last dose
- Women of childbearing potential must use effective contraception during treatment and for at least 6 months after the last dose; men with female partners of reproductive potential should use contraception during treatment and for at least 3 months after the last dose
- Safety and effectiveness in pediatric patients have not been established for approved indications
- Older adults (65+) may experience more side effects, including bone marrow suppression, nerve effects, fatigue, diarrhea, and dehydration — closer monitoring is important
- Mild to moderate kidney impairment does not require a starting dose adjustment; severe renal impairment has not been studied
Overdose
There is no known antidote for paclitaxel overdose. The main risks from too much paclitaxel are severe bone marrow suppression (very low blood counts), nerve damage, and mouth sores. If an overdose is suspected, emergency medical care is needed right away.
Half-Life and How Your Body Processes It
After intravenous infusion, paclitaxel (from albumin-bound formulations) distributes rapidly into tissues and is highly bound to proteins in the blood (about 94%). It is mainly broken down by liver enzymes (CYP2C8 and CYP3A4), with the half-life — the time for half the drug to clear — ranging from roughly 13 to 27 hours. Only a small amount leaves the body through the urine; most is cleared through non-kidney pathways, with about 20% exiting via the stool. Albumin-bound paclitaxel has a larger volume of distribution and faster clearance compared to standard solvent-based paclitaxel injection.
Storage
Store the vials in original cartons between 20° to 25°C (68° to 77°F). Protect from light.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Paclitaxel: Pharmacist Answers to Common Questions
Quick, plain-English answers to the questions patients ask most about Paclitaxel — the kind of thing our pharmacy team would talk through with you at the counter.
Why is paclitaxel given as an IV infusion instead of a pill?
I've heard there are different 'versions' of paclitaxel — does it matter which one I get?
What side effects should I expect, and which ones mean I need to call my doctor right away?
Do I need to take anything before my infusion?
Is it safe to try to get pregnant while on paclitaxel?
Are there any medicines I should avoid while getting paclitaxel?
Is paclitaxel available over the counter?
When was paclitaxel first available?
Who makes paclitaxel?
What is the brand name of paclitaxel?
What is the generic name of Abraxane?
What drug class is paclitaxel?
Is there a generic version of paclitaxel?
What strengths does paclitaxel come in?
Is there a paclitaxel shortage?
Where can I read the paclitaxel prescribing information (package insert)?
Is paclitaxel gluten free?
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Ask Anything About Paclitaxel
Skip the scrolling. Ask in your own words and get an answer from Paclitaxel’s FDA label and our pharmacists’ own work.
Name another drug or a supplement in your question and we check both.
AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
- Sources: Paclitaxel’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
- Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
- Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
- Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.
More About Paclitaxel on HelloPharmacist
Still have a question? A licensed pharmacist answers for free, as soon as they can.Paclitaxel Forms and Strengths (How It Comes)
Paclitaxel comes in 1 dose form, the injection. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Paclitaxel inactive ingredients by manufacturer.
Injection
How this form is used
- Abraxane (and albumin-bound paclitaxel products) is used for metastatic breast cancer after prior combination chemotherapy has failed, first-line non-small cell lung cancer in combination with carboplatin, and first-line metastatic pancreatic adenocarcinoma in combination with gemcitabine
- Paclitaxel injection (solution/concentrate) is used for advanced ovarian cancer, breast cancer after failed chemotherapy, first-line non-small cell lung cancer in combination with cisplatin, adjuvant node-positive breast cancer, and second-line AIDS-related Kaposi's sarcoma
- Abraxane and albumin-bound formulations are given as an intravenous infusion on a schedule set by your oncologist; do not substitute Abraxane or albumin-bound products for other paclitaxel formulations — they are not interchangeable
- Paclitaxel injection (solution) requires pre-medications (a steroid, antihistamine, and acid reducer) before each dose to help prevent serious allergic reactions
- The infusion site must be closely monitored for leakage (extravasation) during and after administration
- Paclitaxel injection solution should be stored and administered using non-PVC containers and tubing to avoid exposure to the plasticizer DEHP
Paclitaxel on the U.S. Market: Products, Makers and Brands
How Paclitaxel appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
20 companies list 39 Paclitaxel product records with the FDA, mostly as injection; the earliest marketing or approval year on record is 1992. Brand names in the directory today include Abraxane and Paclitaxel Protein Bound Particles Albumin Bound; the rest are generics.
Also listed with the FDA, not a patient dose form: Powder (19) · Unfinished injection (1) · Unfinished injection, powder, for solution (1) · Unfinished injection, powder, lyophilized, for suspension (1) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How Widely Paclitaxel Is Used (Medicaid Data)
How many Paclitaxel prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.
How commonly is Paclitaxel prescribed? Of the 1,682 medications we measure, Paclitaxel ranks #618 by Medicaid prescriptions — more than 63% of them.
Utilization by Paclitaxel product
Pick a strength and form to see its own numbers. Brand and generic versions are counted together.
paclitaxel 6 MG/ML Injectable Solution Most dispensed
23 of 59 listed NDCs had Medicaid claims. RxNorm 312199
paclitaxel 100 MG Injection
7 of 12 listed NDCs had Medicaid claims. RxNorm 583214
Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.
Source: Medicaid State Drug Utilization Data (CMS), all states. 30 of the 71 listed Paclitaxel NDCs had Medicaid claims.
Compare Paclitaxel Products
A representative set of FDA-listed product records for Paclitaxel — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 100 mg/20 mL | Intravenous | Abraxis BioScience, LLC | NDA | View NDC → |
| 6 mg/mL | Intravenous | Alembic Pharmaceuticals Inc. × 3 listings | ANDA | View NDC → |
| 6 mg/mL | Intravenous | Alembic Pharmaceuticals Limited × 3 listings | ANDA | View NDC → |
| 100 mg/20 mL | Intravenous | American Regent, Inc. | NDA | View NDC → |
| 6 mg/mL | Intravenous | BluePoint Laboratories × 2 listings | ANDA | View NDC → |
| 100 mg/20 mL | Intravenous | BluePoint Laboratories | ANDA | View NDC → |
| 6 mg/mL | Intravenous | Bryant Ranch Prepack | ANDA | View NDC → |
| 6 mg/mL | Intravenous | Fresenius Kabi USA, LLC | ANDA | View NDC → |
| 6 mg/mL | Intravenous | Gland Pharma Limited × 3 listings | ANDA | View NDC → |
| 6 mg/mL | Intravenous | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. × 3 listings | ANDA | View NDC → |
| 6 mg/mL | Intravenous | Hospira, Inc. × 2 listings | ANDA | View NDC → |
| 100 mg/20 mL | Intravenous | Meitheal Pharmaceuticals Inc. | ANDA | View NDC → |
| 100 mg/20 mL | Intravenous | Mylan Institutional LLC | ANDA | View NDC → |
| 6 mg/mL | Intravenous | Natco Pharma USA LLC × 3 listings | ANDA | View NDC → |
| 100 mg/100 mg | Intravenous | Ningbo Shuangcheng Pharmaceutical Co., Ltd | ANDA | View label ↗ |
| 6 mg/mL | Intravenous | Northstar Rx LLC | ANDA | View NDC → |
| 100 mg/20 mL | Intravenous | NorthStar Rx LLC | ANDA | View NDC → |
| 6 mg/mL | Intravenous | Novadoz Pharmaceuticals LLC × 3 listings | ANDA | View NDC → |
| 6 mg/mL | Intravenous | Sagent Pharmaceuticals | ANDA | View NDC → |
| 100 mg/20 mL | Intravenous | Sandoz Inc | ANDA | View NDC → |
| 6 mg/mL | Intravenous | Teva Parenteral Medicines, Inc. × 4 listings | ANDA | View NDC → |
| 100 mg/20 mL | Intravenous | Teva Pharmaceuticals, Inc. | NDA | View NDC → |
Showing 39 of 39 products — FDA National Drug Code Directory. See every product, package size and price: browse all 39 Paclitaxel NDCs →
Paclitaxel Side Effects Reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Paclitaxel — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Paclitaxel in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Paclitaxel FDA Approval History
How Paclitaxel went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Paclitaxel Recall History
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Paclitaxel recalls since July 2021.
✅No Paclitaxel recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.
Paclitaxel in RxNorm: From Ingredient to Every Form and Strength
RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.
- Dose forms
- 2
- Strengths
- 2
- Forms in current FDA listings
- 2 of 2
RxCUI 56946 RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Paclitaxel Supply and Shortage Status
Whether Paclitaxel is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
Paclitaxel Brand Names
Paclitaxel has 2 brand names on record: Abraxane and Paclitaxel Protein Bound Particles Albumin Bound. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.
Who Makes Paclitaxel: Manufacturers and Labelers
20 companies list Paclitaxel products with the FDA. By number of product records, the largest are Teva Parenteral Medicines, Inc., Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Sources for This Paclitaxel Page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Teva Pharmaceuticals, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →